艾吉纳斯公司在2025年欧洲肿瘤内科学会(ESMO)会议上报告多个难治性固体肿瘤患者中,两年存活率达到39%

美股速递
Oct 17

艾吉纳斯公司在2025年欧洲肿瘤内科学会(ESMO)会议上报告,多个难治性固体肿瘤患者接受BOT/Bal治疗后,两年存活率为39%。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10